NYSE:BVS Bioventus (BVS) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free BVS Stock Alerts $3.98 -0.09 (-2.21%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$3.95▼$4.0950-Day Range$3.98▼$5.7552-Week Range$0.86▼$6.08Volume128,404 shsAverage Volume144,784 shsMarket Capitalization$315.10 millionP/E RatioN/ADividend YieldN/APrice Target$7.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Bioventus alerts: Email Address Bioventus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside92.6% Upside$7.67 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$80,435 Sold Last QuarterProj. Earnings Growth150.00%From $0.16 to $0.40 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.10 out of 5 starsMedical Sector347th out of 908 stocksSurgical & Medical Instruments Industry43rd out of 96 stocks 3.5 Analyst's Opinion Consensus RatingBioventus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioventus has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for BVS. Previous Next 0.0 Dividend Strength Dividend YieldBioventus does not currently pay a dividend.Dividend GrowthBioventus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BVS. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 1 people have searched for BVS on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows3 people have added Bioventus to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bioventus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $80,435.00 in company stock.Percentage Held by Insiders29.10% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Bioventus are expected to grow by 150.00% in the coming year, from $0.16 to $0.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bioventus is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bioventus is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioventus has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Bioventus Stock (NYSE:BVS)Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Read More BVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BVS Stock News HeadlinesApril 16, 2024 | insidertrades.comInsider Selling: Bioventus Inc. (NYSE:BVS) SVP Sells 3,054 Shares of StockMarch 26, 2024 | insidertrades.comBioventus Inc. (NYSE:BVS) CFO Sells $29,865.99 in StockApril 26, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 17, 2024 | investing.comBioventus CFO sells shares worth $19,000April 16, 2024 | americanbankingnews.comBioventus Inc. (NYSE:BVS) SVP Anthony D'adamio Sells 3,054 Shares of StockApril 16, 2024 | americanbankingnews.comBioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton Sells 4,000 Shares of StockMarch 13, 2024 | bizjournals.comDurham public company resets priorities under new CEOMarch 13, 2024 | finance.yahoo.comBioventus Inc. (NASDAQ:BVS) Q4 2023 Earnings Call TranscriptApril 26, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)March 12, 2024 | markets.businessinsider.comWhat Wall Street expects from Repro Medical System's earningsMarch 12, 2024 | msn.comBioventus Non-GAAP EPS of $0.07 beats by $0.05, revenue of $135.42M beats by $11.46MMarch 12, 2024 | finance.yahoo.comBioventus Inc (BVS) Reports Growth in Q4 Sales and Adjusted EBITDA, Provides Optimistic 2024 ...March 12, 2024 | globenewswire.comBioventus Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 12, 2024 | nz.finance.yahoo.comBioventus Inc. (BVS) stock price, news, quote & history – Yahoo FinanceMarch 11, 2024 | benzinga.comA Preview Of Bioventus's EarningsMarch 4, 2024 | globenewswire.comBioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024February 15, 2024 | wsj.comBioventus Inc. Cl AJanuary 24, 2024 | seekingalpha.comBioventus: Bullish On Path To ProfitabilityJanuary 19, 2024 | finanznachrichten.deBioventus, Inc.: Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational FlexibilityJanuary 12, 2024 | finance.yahoo.comBioventus Announces Inducement Equity to President and Chief Executive Officer Robert ClaypooleDecember 27, 2023 | businesswire.comBIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmDecember 21, 2023 | benzinga.comBioventus Stock (NASDAQ:BVS) Dividends: History, Yield and DatesDecember 20, 2023 | bizjournals.comDurham public company names new CEO at critical junctureDecember 19, 2023 | finance.yahoo.comBioventus Names Robert Claypoole as President and Chief Executive OfficerDecember 16, 2023 | msn.comBioventus Inc - (BVS) Price Target Increased by 34.58% to 6.63December 8, 2023 | msn.comCanaccord Genuity Upgrades Bioventus Inc - (BVS)November 27, 2023 | msn.comBioventus Inc - (BVS) Price Target Increased by 7.33% to 4.93See More Headlines Receive BVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today4/26/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:BVS CUSIPN/A CIK1665988 Webwww.bioventus.com Phone919-474-6700FaxN/AEmployees970Year FoundedN/APrice Target and Rating Average Stock Price Target$7.67 High Stock Price Target$9.00 Low Stock Price Target$7.00 Potential Upside/Downside+93.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.52) Trailing P/E RatioN/A Forward P/E Ratio24.81 P/E GrowthN/ANet Income$-156,230,000.00 Net Margins-30.49% Pretax Margin-23.64% Return on Equity2.25% Return on Assets0.62% Debt Debt-to-Equity Ratio1.66 Current Ratio1.53 Quick Ratio1.01 Sales & Book Value Annual Sales$512.34 million Price / Sales0.61 Cash Flow$0.76 per share Price / Cash Flow5.25 Book Value$2.80 per share Price / Book1.42Miscellaneous Outstanding Shares79,170,000Free Float56,129,000Market Cap$314.30 million OptionableNot Optionable Beta0.50 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Mark L. Singleton (Age 54)Senior VP & CFO Comp: $444.12kMr. Robert Claypoole (Age 52)President, CEO & Director Mr. Mike Crowe B.S.M.B.A., Senior Vice President of OperationsMr. David CrawfordVice President of Investor Relations & TreasurerMr. Anthony D'Adamio (Age 63)Senior VP, General Counsel & Corporate Secretary Comp: $618.29kMs. Katrina J. Church J.D. (Age 62)Senior VP & Chief Compliance Officer Ms. Helen LeupoldSenior VP & Chief Human Resources OfficerMr. Larry ChenManaging Director of China & Asia PacificMore ExecutivesKey CompetitorsTactile Systems TechnologyNASDAQ:TCMDNeuroPaceNASDAQ:NPCEFractyl HealthNASDAQ:GUTSLyra TherapeuticsNASDAQ:LYRACVRxNASDAQ:CVRXView All CompetitorsInsiders & InstitutionsAnthony D'adamioSold 3,054 sharesTotal: $14,506.50 ($4.75/share)Mark Leonard SingletonSold 4,000 sharesTotal: $19,000.00 ($4.75/share)GSG Advisors LLCBought 9,500 shares on 4/11/2024Ownership: 0.033%Quadrature Capital LtdBought 16,031 shares on 3/25/2024Ownership: 0.020%Mark Leonard SingletonSold 5,541 sharesTotal: $29,865.99 ($5.39/share)View All Insider TransactionsView All Institutional Transactions BVS Stock Analysis - Frequently Asked Questions Should I buy or sell Bioventus stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bioventus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BVS shares. View BVS analyst ratings or view top-rated stocks. What is Bioventus' stock price target for 2024? 3 Wall Street analysts have issued 1 year price targets for Bioventus' shares. Their BVS share price targets range from $7.00 to $9.00. On average, they anticipate the company's share price to reach $7.67 in the next twelve months. This suggests a possible upside of 92.6% from the stock's current price. View analysts price targets for BVS or view top-rated stocks among Wall Street analysts. How have BVS shares performed in 2024? Bioventus' stock was trading at $5.27 at the beginning of the year. Since then, BVS shares have decreased by 24.5% and is now trading at $3.98. View the best growth stocks for 2024 here. When is Bioventus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our BVS earnings forecast. How were Bioventus' earnings last quarter? Bioventus Inc. (NYSE:BVS) announced its earnings results on Tuesday, March, 12th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. The firm earned $135.42 million during the quarter, compared to analyst estimates of $124.84 million. Bioventus had a positive trailing twelve-month return on equity of 2.25% and a negative net margin of 30.49%. What guidance has Bioventus issued on next quarter's earnings? Bioventus updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided EPS guidance of 0.120-0.200 for the period, compared to the consensus EPS estimate of 0.330. The company issued revenue guidance of $520.0 million-$535.0 million, compared to the consensus revenue estimate of $517.8 million. When did Bioventus IPO? Bioventus (BVS) raised $126 million in an initial public offering (IPO) on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO. Who are Bioventus' major shareholders? Bioventus' stock is owned by a number of institutional and retail investors. Top institutional investors include GSG Advisors LLC (0.03%). Insiders that own company stock include Anthony D'adamio, Anthony P Bihl III, John A Bartholdson, John Nosenzo, Juniper Investment Company, Ll, Katrina J Church, Kenneth Michael Reali, Mark Leonard Singleton and William A Hawkins. View institutional ownership trends. How do I buy shares of Bioventus? Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:BVS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
